Development of an Assay for the diagnosis of Neuralgic Amyotrophy

Development of an Assay for the diagnosis of Neuralgic Amyotrophy - DANA-Trial

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00036067

Enrollment

Registered

2025-03-04

Start date

2024-07-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G54.5

Interventions

Group 1: In this study, patients are systematically recruited and undergo a comprehensive diagnostic evaluation. This includes the creation of a detailed patient catalog as well as clinical examinatio

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Age = 18 years - Diagnosis of acute neuralgic amyotrophy up to 4 weeks after onset of symptoms - Informed consent and signed consent

Exclusion criteria

Exclusion criteria: Persons in a dependent or employment relationship with the examiner Placement in an institution by order of a court or government agency Patient incapable of contracting Pregnancy and breastfeeding

Design outcomes

Primary

Measure	Time frame
Detection of disease-specific surface proteins	—

Secondary

Measure	Time frame
Development after 3 months: Correlation - of clinical phenotype with antibody pattern - of clinical course with antibody pattern - of nerve sonographic findings with antibody pattern	—

Countries

Germany

Contacts

Public ContactJohannes Holle

Klliniken der Stadt Köln gGmbH

hollej@kliniken-koeln.de+49221890713621

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026